

Celiac Disease: A Review from Genetic to Treatment

Erfaneh Jafari¹, Niloufar Soleymani², Masoud Hamidi^{3*}, Azar Rahi⁴, Akram Rezaei⁵, Reza Azizian^{1,6*}

¹Pediatric Infectious Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran; ²Department of Food Hygiene, Islamic Azad University (Science and Research Branch), Tehran, Iran; ³École Polytechnique de Bruxelles-BioMatter Unit, Université Libre de Bruxelles (ULB), Brussels, Belgium; ⁴Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; ⁵Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; ⁶Biomedical Innovation and Start-Up Association (Biomino), Tehran University of Medical Sciences, Tehran, Iran

OPEN ACCESS

Received: September 17, 2023

Accepted: November 29, 2023

Published online: December 2, 2023

Citation:

Jafari E, Soleymani N, Hamidi M, Rahi A, Rezaei A, Azizian R. Celiac Disease: A Review from Genetic to Treatment. *Iran Biomed J.* 2024; 28(1): 8-14.

ABSTRACT

Celiac disease is a complex disorder influenced by genetic and environmental factors. When people with a genetic predisposition to CD consume gluten, an inflammatory response is triggered in the small intestine, and this reaction can be alleviated by the elimination of gluten from the diet. The clinical manifestations of CD vary greatly from person to person and begin at a young age or in adulthood. Influence of genetic factors on CD development is evident in carriers of the DQ2 and/or DQ8 allele. HLA genotypes are associated with gut colonization by bacteria, particularly in individuals suffering from CD. In addition, beneficial gut microbes are crucial for the production of DPP-4, which plays a key role in immune function, as well as metabolic and intestinal health. Therefore, probiotics have been recommended as a complementary food supplement in CD.

DOI: 10.61186/ibj.4028

Keywords: Celiac disease, Dipeptidyl peptidase 4, HLA-DQ antigens, Probiotics

Corresponding Authors:

Masoud Hamidi

École Polytechnique de Bruxelles-BioMatter Unit, Université Libre de Bruxelles (ULB), Brussels, Belgium; Tel.: (+98-21) 55365433;

E-mail: m.hamidi2008@gmail.com

Reza Azizian

Pediatric Infectious Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran; Tel.: (+98-21) 61472199;

E-mail: r.azizian65@gmail.com

INTRODUCTION

Celiac disease is an autoimmune disorder that causes reactions of both the innate and adaptive immune system. CD is involved in the gastrointestinal tract infection, mainly the small gut. The persistent inflammatory reaction is triggered by consuming gluten-containing products (e.g., wheat, barley, and rye) and subsides when gluten is removed from the diet. The development of CD, with an estimated incidence of 1% in the Western population, is closely linked to the MHC class II molecules. Among CD patients, around 3% possesses HLA-DQ alleles. In addition, an increased risk of developing CD is observed in individuals whose first-degree relatives are affected

by the disease. The role of genetic factors in CD development is evident in families in which at least one member has CD^[1-4].

Indicators for CD

The CD is an intricate disease triggered by various factors, including genetic and environmental elements. In people with a genetic predisposition (as an example, the presence of HLA genes such as HLA-DQ2 or HLA-DQ-8), exposure to gluten is necessary but not sufficient for disease development. The exposure of these individuals to gluten and environmental elements causes the activation of their innate and adaptive immune responses^[5]. Therefore, the signs and symptoms of the disease can vary greatly from case to case. The clinical

List of Abbreviations:

APC: antigen-presenting cell; **CD:** celiac disease; **DPP-4:** dipeptidyl peptidase-4; **EMA:** endomysial antibodies; **HLA:** human leukocyte antigen; **IBS:** irritable bowel syndrome; **TCR:** T-cell receptor; **TG2:** transglutaminase 2

manifestation of CD ranges from asymptomatic (silent) to symptomatic (full-blown acute or chronic), associated with abdominal distension and pain, iron deficiency anemia, peripheral neuropathy, decreased bone mass, bone fractures, and elevated liver enzyme levels. Despite the frequency of diagnosis of chronic CD, there is a widespread belief that the boundaries of CD are blurred^[2,3].

Diagnosis of CD

CD is a long-term disease that affects the gut and often arises from an inability to absorb nutrients due to gluten intolerance^[2,6]. In addition, the microbiota has a decisive role in developing autoimmune and atopic diseases^[7]. CD can occur early in life or later in adulthood^[8] with varying symptoms, particularly typical gastrointestinal symptoms such as abdominal cramps, bloating, flatulence, diarrhea, vomiting, foul-smelling urine, and pale-colored stools (steatorrhea). However, some patients have alternative symptoms; i.e., non-intestinal manifestations or nutritional deficiencies. Common extraintestinal manifestations include late puberty, short stature, fatigue, and iron deficiency anemia^[9]. CD can manifest itself very subtly, and it may be confused with IBS. Therefore, patients presenting with the above-mentioned signs and symptoms have to be screened for CD^[10]. Serological testing of antibodies is important in the diagnosis of CD and depends on the ingestion of gluten. The positive tests of TTG-IgA/IgG and IgA-EMA, accompanied by a small intestine biopsy, will define the genetic tests for the evaluation of patients on a gluten-free diet^[11]. In all patients with CD, DQ2 and/or DQ8 class II HLA types have been identified, although the major utility of a genetic test is its negative predictive value. Therefore, for ruling out CD, further testing is needed^[11,12]. CD symptoms are characterized by intraepithelial lymphocytosis and small-bowel biopsies and are classified according to Marsh or Marsh-modified. If both serologic assessments and the biopsy are positive, CD diagnosis would be considered definite. However, if positive serologic assessments with excessive antibody titers accompany a negative biopsy, the adequate diagnosis of CD is halted^[13].

Treatment of CD

The beneficial options for CD treatment are categorized into the following strategies: (a) eliminating toxic gluten peptides before they reach the intestine, (b) regulating the immunostimulatory elements of toxic gluten peptides; (c) modifying intestinal penetrability; (d) modulating immune system and forming gluten tolerance; and (e) controlling the imbalance in the intestine microbiota via immunotherapy, a promising strategy for treating the IgE-mediated wheat allergy^[14].

Currently, the gluten-free diet is not always the only treatment proposed for CD as it is ineffective in all patients^[13,15]. Oral enzyme therapy is another attractive approach that inactivates gluten peptides in the digestive tract^[16]. Some microorganisms contain proteases that can degrade gluten peptides rich in glutamine and proline residues^[17,18]. Therefore, probiotic preparations are suggested as a complementary dietary treatment for CD patients. In adult patients with IBS, the consumption of predigested gliadins without α -gliadin peptides was found to improve disease indicators^[19,20].

Genetic disposition of CD

Genetic background has an important role in the predisposition to CD. The HLA-DQ2 haplotype (DQA1*0501-DQB1*0201) is present in the majority of CD-affected individuals (90%), while the HLA-DQ8 haplotype (DQA1*0301-DQB1*0302) is found in 5% of these cases, which carry at least one of the two DQ2 alleles, especially DQB1*0201^[21]. Both haplotypes are involved in CD development and expressed on the surface of APCs. These cells feature a strong affinity for deamidated gluten-derived peptides, which bind and present to CD4 T cells in suburothelium, starting up the inflammatory cascade, which is a function of CD. Auto-antibodies against TG2, specifically anti-TG2 and anti-EMA, are responsible for the deamination of gluten in CD patients^[22,23]. However, the most important alteration is intestinal damage, often characterized by villous atrophy, a scientific feature in most CD cases. The binding properties of gluten-derived peptides and the ability to elicit an immunologic reaction depend on the exact HLA-DQ molecules found in each individual, with a dose-based effect. HLA-DQ2.5 has the potential to bind to the most important variety of immune-dominant gluten peptides and also has the high ability to form strong complexes with these peptides on APC. Therefore, individuals with the HLA-DQ2.5 heterodimer have a higher risk of developing CD, especially if they carry two HLA-DQB1*02 alleles (double dose). Individuals with HLA-DQ8 or only the HLA-DQB1*02 allele (HLA-DQ2.2 receptor) have the lowest risk of developing CD, and those with only the HLA-DQA1*05 allele (HLA-DQ7.5 receptor) have the lowest likelihood for CD development^[22,24].

Association of HLA-DQ with CD

CD is a polygenic and multifactorial disease, with genetic and environmental factors involved in its pathogenesis. A strong association of HLA-DQ alleles with CD has been demonstrated in various studies^[25,26]. The alleles HLA-DQA1*05 and HLA-DQB1*02 encode the HLA-DQ2 heterodimers α -subunit and β -subunit, respectively. These alleles can occur on

identical chromosomes in *cis* configuration (DR3/DQ2 haplotype) or on homologous chromosomes, in *trans* configuration (DR5/DQ7 and DR5/DQ2 haplotypes). There are two types of DQ2 heterodimers: DQ2.5 (DQA1*0501/B1*0201) and DQ2.2 (DQA1*0201/B1*0202)^[27]. Patients with DQ2.5 heterodimers have a higher risk for CD development than those with DQ2.2 heterodimers^[28]. Although DQ2.2 molecules are structurally very similar to DQ2.5 molecules, the gluten peptide-binding properties of DQ2.2 are less pronounced. The number of HLA DQB1*0201 copies in CD patients may have important implications. Heterozygotes can synthesize 4 $\alpha\beta$ -chain combinations, whereas in homozygotes, all HLA-DQ molecules are identical^[27,28]. In determining the risk, the presence of the second β -chain appears to be critical, while that of the second α -chain is less significant^[28]. Experimental data have shown a correlation between the number of HLA-DQ2.5 molecules and CD risk; HLA-DQ2.5 homozygotes can present gluten peptides more successfully on APCs than HLA-DQ2.5 heterozygotes, leading to five-fold CD risk^[27]. The gene dose of the HLA-DQ2 alleles expressed by APC, determines the strength of the immune response. HLA-DQ2.5 homozygotes show maximal T-cell activation and pro-inflammatory response, while heterozygotes show much less pronounced responses. In immunological *in vitro* studies, having HLA-DQ2 homozygosity may change the progression of CD. This is because carrying DQB1*02 alleles leads to a significant influence on gene dosage, ultimately resulting in an increased likelihood of complications as seen in clinical settings.^[27,28]

HLA type as a target for CD Treatment

The most uncomplicated treatment for CD is a gluten-free diet, but major efforts have been taken to expand alternative remedies. Two different approaches pursued by researchers include blocking peptides and recombinant TCR ligands. Gluten in the intestine is markedly resistant to enzymatic digestion, leading to the formation of proteolytic-resistant gluten peptides by physiological processes. These peptides can effectively activate disease-associated T cells through an HLA-mediated technique. The goal of such therapies is to convert these naturally occurring T cell-stimulating substances into inhibitors of HLA-mediated antigen presentation. These therapies pay special attention to HLA-DQ2.5 due to its high prevalence in patients with CD and the thorough investigating immune-dominant epitopes associated with it^[29]. Blocking peptides are short sections of deamidated gliadin that have been designed to attach to the HLA-DQ2 groove without activating gliadin-responsive T cells with reduced activation. Some peptides have demonstrated affinity

for the HLA-DQ2 receptor and inhibited T-cell proliferation, potentially serving as HLA blockers. Recombinant TCR ligands are partial HLA molecules that encompass the $\alpha 1$ and $\beta 1$ domains of the HLA-DQ molecule and are bound to unique antigenic peptides^[30]. This method has shown promise in preclinical models when targeting for inactivation of gliadin-reactive T cells, although its *in vivo* efficacy and protection remain uncertain^[31]. One challenge of this method is that the proposed strategies focused on HLA can also impact different immune responses. Moreover, the blockers have displayed moderate efficacy in inhibiting gluten-triggered T-cell activation *in vitro*^[29,32].

Microbiota and CD

Factors contributing to CD include genetics, prenatal influences, infections, and microbiota composition^[33]. Bacteria such as *Prevotella* spp. and *Streptococcus* spp. have been found more frequently in children under two years of age and adults suffering from CD^[34,35]. Toll-like receptors from pathogenic bacteria trigger the innate immune system, which activates pro-inflammatory cytokines and Th1, Th2, and Th17 responses^[35,36]. Childhood infections can be considered a risk factor for CD^[37,38]. A Swedish study found that childhood CD has the characteristics of an infectious disease^[39], which peaked between 1985 and 1996 and was also observed in 2001–2004^[40]. Children born with CD showed increased bacterial populations such as *Clostridiales*, *Prevotella*, and *Actinomyces* in the jejunum^[41,42]. About 48 species of *Prevotella* spp. have been isolated from humans, and the oral cavity is the most common site for isolating this bacterium. These bacteria have also been isolated from stool samples^[41,43,44].

Microbiota and HLA in CD

The development of gluten intolerance is associated with the stimulation of gluten-specific CD4⁺ T cells in the lamina propria and the increase in IL-15^[45]. The presence of HLA-DQ2/8 haplotypes is directly related to CD. Studies have confirmed an increase in *Firmicutes* and *Proteobacteria* populations and a decrease in *Actinobacteria* and *Bifidobacteria* populations in infants with HLA-DQ2 and HLA-DQ8 haplotypes, which demonstrate an association between HLA genotypes and colonization of the intestine by bacteria that are typical in CD^[46]. The HLA-DQ2/8 haplotype is also observed in a general population, suggesting that genetics alone does not explain the high prevalence of CD. Furthermore, the gut microbiota in infants with the HLA-DQ2/8 haplotype is influenced by the type of feeding, and breastfeeding has been shown to have a protective effect against CD^[47,48].




Fig. 1. Roles attributed to DPP4.

DPP-4 and CD

DPP-4 is an enzyme that influences metabolic behaviors and gut dysfunction by cleaving hormones and major peptides. This enzyme has various functions. It interacts with other proteins and is expressed in different tissues; therefore, DPP-4 could be used as a marker for a variety of diseases^[49,50] (Fig. 1). Beneficial microbes living in the intestine play an important role in the production of this enzyme. The presence of human DPP-4 homologs has been reported in some commensal bacteria such as *Lactobacillus* and *Prevotella* spp.^[51]. Clinical studies have demonstrated that using prebiotic preparations such as barley, improves the growth of *Prevotella* spp. and positively affects the digestion and absorption of glucose^[52]. Similarly, the activity of DPP-4 as Xaa-pro dipeptidyl-peptidase has been shown in lactic acid-producing bacteria such as *Lactobacillus*, *Lactococcus*, and *Streptococcus*^[53]. Since DPP-4 has an active participation in the immune system, it can be considered a potential target for treating autoimmune diseases such as IBS^[50]. Studies have exhibited a reduction in DPP-4 activity in Crohn's disease patients' bloodstream, plasma, and colon. However, the number of DPP-4-positive lymphocytes is higher in these patients than that of healthy ones^[54]. A DPP-4-like homolog produced by intestinal commensals affects the digestion of dietary proteins; therefore, it can be a suitable host-side response to these foods^[51].

Prevotella spp. as a probiotic

The main source of carbohydrate substrates available to the gut microbiota is the dietary fiber in the human diet. Therefore, it is possible to support the host's immune system by modifying the diet of the gut microbiota^[55]. One of the most important mechanisms of probiotics in strengthening the host immune system is the prevention of colonization by occupying bacterial binding sites^[56]. Researchers have exhibited that a diet rich in fiber, fat, and protein increases *Prevotella* spp. in the intestine, while a high consumption of fat and protein leads to an increase in *Bacteroides*^[57]. Clinical studies have displayed that using prebiotic compounds such as barley as a dietary supplement, improves the growth of *Prevotella* spp. and positively affects the digestion and absorption of glucose^[58]. Using barley as a prebiotic also results in a high *Prevotella/Bacteroides* ratio, which may benefit for cardiometabolic regulation. Therefore, the role of *Prevotella* spp. in improving the digestion and absorption of glucose has been confirmed^[59].

CONCLUSION

CD is a multifaceted disorder that is affected by a combination of genetic and environmental factors. The clinical presentation of CD varies across individuals and can manifest at different stages of life influenced by the

interplay between HLA haplotypes, feeding practices, and gut microbiota composition. Probiotics have emerged as a promising adjunct therapy for managing CD by promoting a healthy gut microbiome and optimizing immune function. Moreover, early identification and intervention in susceptible individuals, such as those with HLA haplotypes associated with increased CD risk, can aid in disease prevention. Moving forward, a complete approach that considers genetic susceptibility, microbiome modulation, and dietary interventions should be integrated into the management of CD to improve outcomes and enhance overall well-being.

DECLARATIONS

Acknowledgments

The proofreading of the present study was carried out with instatext (<https://instatext.io>).

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

All authors reviewed and approved the final version of the manuscript.

Authors' contributions

EJ: formed the concept of the work, prepared the picture, and reviewed and edited the work; NS: wrote the initial draft; MH: reviewed and edited the work and prepared the work for submission; AzR and AkR: wrote the initial draft; RA: formed the concept of the work and prepared the work for submission.

Data availability

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Supplementary information

The online version does not contain supplementary material.

REFERENCES

1. Jedwab CF, Roston BCdMB, Toge ABfD, Echeverria IF, Tavares GOG, Alvares MA, et al. O papel dos probióticos na resposta imunológica e na microbiota fecal de crianças com doença celíaca: uma revisão sistemática. *Rev Paul Pediatr*. 2022; 40:e2020447.
2. Holtmeier W, Caspary WF. Celiac disease. *Orphanet J Rare Dis*. 2006; 1:3.
3. Tonutti E, Bizzaro N. Diagnosis and classification of celiac disease and gluten sensitivity. *Autoimmun Rev*. 2014; 13(4-5):472-6.
4. Björck S, Lynch K, Brundin C, Agardh D. Repeated screening can be restricted to at-genetic-risk birth cohorts. *J Pediatr Gastroenterol Nutr*. 2016; 62(2):271-5.
5. Green PH, Lebwohl B, Greywoode R. Celiac disease. *J Allergy Clin Immunol*. 2015; 135(5):1099-106.
6. Poddighe D, Rebuffi C, De Silvestri A, Capittini C. Carrier frequency of HLA-DQB1* 02 allele in patients affected with celiac disease: A systematic review assessing the potential rationale of a targeted allelic genotyping as a first-line screening. *World J Gastroenterol*. 2020; 26(12):1365-81.
7. Sarno M, Discepolo V, Troncone R, Auricchio R. Risk factors for celiac disease. *Ital J Pediatr*. 2015; 41:57.
8. Kelly CP, Bai JC, Liu E, Leffler DA. Advances in diagnosis and management of celiac disease. *Gastroenterology*. 2015; 148(6):1175-86.
9. Itzlinger A, Branchi F, Elli L, Schumann M. Gluten-free diet in celiac disease—forever and for all? *Nutrients*. 2018; 10(11):1796.
10. Rubio Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA, American College of Gastroenterology. ACG clinical guidelines: diagnosis and management of celiac disease. *Am J Gastroenterol*. 2013; 108(5):656-76.
11. Sahin Y. Celiac disease in children: A review of the literature. *World J Clin Pediatr*. 2021; 10(4):53-71.
12. de Lourdes Moreno M, Cebolla Á, Muñoz-Suano A, Carrillo-Carrion C, Comino I, Pizarro Á, et al. Detection of gluten immunogenic peptides in the urine of patients with coeliac disease reveals transgressions in the gluten-free diet and incomplete mucosal healing. *Gut*. 2017; 66(2):250-7.
13. Cichewicz AB, Mearns ES, Taylor A, Boulanger T, Gerber M, Leffler DA, et al. Diagnosis and treatment patterns in celiac disease. *Dig Dis Sci*. 2019; 64:2095-106.
14. Cianferoni A. Wheat allergy: diagnosis and management. *J Asthma Allergy*. 2016; 9:13-25.
15. Ilus T, Kaukinen K, Virta L, Huhtala H, Mäki M, Kurppa K, et al. Refractory coeliac disease in a country with a high prevalence of clinically-diagnosed coeliac disease. *Aliment Pharmacol Ther*. 2014; 39(4):418-25.
16. Moreno Amador MdL, Sánchez Muñoz D, Sanders D, Rodríguez Herrera A, Sousa Martín C. Verifying diagnosis of refractory celiac disease with urine gluten immunogenic peptides as biomarker. *Front Med*. 2020; 7: 601854.
17. Picozzi C, Mariotti M, Cappa C, Tedesco B, Vigentini I, Foschino R, et al. Development of a Type I gluten-free

- sourdough. *Lett Appl Microbiol.* 2016; 62(2):119-25.
18. Singhvi N, Gupta V, Gaur M, Sharma V, Puri A, Singh Y, et al. Interplay of human gut microbiome in health and wellness. *Indian J Microbiol.* 2020; 60(1):26-36.
 19. Francavilla R, Piccolo M, Francavilla A, Polimeno L, Semeraro F, Cristofori F, et al. Clinical and microbiological effect of a multispecies probiotic supplementation in celiac patients with persistent IBS-type symptoms. *J Clin Gastroenterol.* 2019; 53(3):e117.
 20. Håkansson Å, Andrén Aronsson C, Brundin C, Oscarsson E, Molin G, Agardh D. Effects of *Lactobacillus plantarum* and *Lactobacillus paracasei* on the peripheral immune response in children with celiac disease autoimmunity: a randomized, double-blind, placebo-controlled clinical trial. *Nutrients.* 2019; 11(8):1925.
 21. Johnson TC, Diamond B, Memeo L, Negulescu H, Hovhanissyan Z, Verkarre V, et al. Relationship of HLA-DQ8 and severity of celiac disease: comparison of New York and Parisian cohorts. *Clin Gastroenterol Hepatol.* 2004; 2(10):888-94.
 22. Sollid LM, Jabri B. Triggers and drivers of autoimmunity: lessons from coeliac disease. *Nat Rev Immunol.* 2013; 13(4):294-302.
 23. Farsimadan M, Heravi FS, Emamvirdizadeh A, Moradi S, Iranpour H, Tabasi E, et al. Evaluation of helicobacter pylori genotypes in obese patients with gastric ulcer, duodenal ulcer, and gastric cancer: an observational study. *Dig Dis.* 2022; 40(3):355-61.
 24. Martínez Ojinaga E, Fernández-Prieto M, Molina M, Polanco I, Urcelay E, Núñez C. Influence of HLA on clinical and analytical features of pediatric celiac disease. *BMC Gastroenterol.* 2019; 19:91.
 25. Heap GA, van Heel DA. Genetics and pathogenesis of coeliac disease. *Semin Immunol.* 2009; 21(6):346-54.
 26. Zamani M, Modares Sadegi M, Shirvani F, Zamani H, Emami M. The involvement of the HLA-DQB 1 alleles in the risk and the severity of Iranian coeliac disease patients. *Int J Immunogenet.* 2014; 41(4):312-7.
 27. Bajor J, Szakács Z, Farkas N, Hegyi P, Illés A, Solymár M, et al. Classical celiac disease is more frequent with a double dose of HLA-DQB1* 02: A systematic review with meta-analysis. *Plos One.* 2019; 14(2):e0212329.
 28. D'Avino P, Serena G, Kenyon V, Fasano A. An updated overview on celiac disease: from immuno-pathogenesis and immuno-genetics to therapeutic implications. *Expert Rev Clin Immunol.* 2021; 17(3):269-84.
 29. Sollid LM, Tye Din JA, Qiao SW, Anderson RP, Gianfrani C, Koning F. Update 2020: nomenclature and listing of celiac disease-relevant gluten epitopes recognized by CD4+ T cells. *Immunogenetics.* 2020; 72(1-2):85-8.
 30. Anderson RP, Degano P, Godkin AJ, Jewell DP, Hill AV. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. *Nat Med.* 2000; 6(3):337-42.
 31. Huan J, Meza-Romero R, Mooney JL, Vandenbark AA, Offner H, Burrows GG. Single-chain recombinant HLA-DQ2. 5/peptide molecules block α 2-gliadin-specific pathogenic CD4+ T-cell proliferation and attenuate production of inflammatory cytokines: a potential therapy for celiac disease. *Mucosal Immunol.* 2011; 4(1):112-20.
 32. Espino L, Núñez C. The HLA complex and coeliac disease. *Int Rev Cell Mol Biol.* 2021; 358:47-83.
 33. Gholam Mostafaei FS, Rostami-Nejad M, Emadi A, Yadegar A, Asadzadeh Aghdai H, Zali MR. Changes in the composition and function of the gut microbiota in celiac disease. *Koomesh.* 2021; 23(3):301-16.
 34. Olivares M, Neef A, Castillejo G, De Palma G, Varea V, Capilla A, et al. The HLA-DQ2 genotype selects for early intestinal microbiota composition in infants at high risk of developing coeliac disease. *Gut.* 2015; 64(3):406-17.
 35. Sjöberg V, Sandström O, Hedberg M, Hammarström S, Hernell O, Hammarström ML. Intestinal T-cell responses in celiac disease—impact of celiac disease associated bacteria. *Plos One.* 2013; 8(1):e53414.
 36. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. *Cell.* 2009; 139(3):485-98.
 37. Myléus A, Hernell O, Gothefors L, Hammarström ML, Persson LÅ, Stenlund H, et al. Early infections are associated with increased risk for celiac disease: an incident case-referent study. *BMC Pediatr.* 2012; 12:194.
 38. Olivares M, Laparra JM, Sanz Y. Host genotype, intestinal microbiota and inflammatory disorders. *Br J Nutr.* 2013; 109(S2):S76-S80.
 39. Ivarsson A, Persson L, Nyström L, Ascher H, Cavell B, Danielsson L, et al. Epidemic of coeliac disease in Swedish children. *Acta Paediatr.* 2000; 89(2):165-71.
 40. Olsson C, Hernell O, Hörnell A, Lönnberg Gr, Ivarsson A. Difference in celiac disease risk between Swedish birth cohorts suggests an opportunity for primary prevention. *Pediatrics.* 2008; 122(3):528-34.
 41. Kalia VC, Gong C, Shanmugam R, Lin H, Zhang L, Lee JK. The emerging biotherapeutic agent: Akkermansia. *Indian J Microbiol.* 2022; 62(1):1-10.
 42. Kim S, Covington A, Pamer EG. The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens. *Immunol Rev.* 2017; 279(1):90-105.
 43. Dewhirst FE, Chen T, Izard J, Paster BJ, Tanner AC, Yu WH, et al. The human oral microbiome. *J Bacteriol.* 2010; 192(19):5002-17.
 44. Hayashi H, Shibata K, Sakamoto M, Tomita S, Benno Y. *Prevotella copri* sp. nov. and *Prevotella stercora* sp. nov., isolated from human faeces. *Int J Syst Evol Microbiol.* 2007; 57(Pt 5):941-6.
 45. Cukrowska B, Sowińska A, Bierła JB, Czarnowska E, Rybak A, Grzybowska Chlebowczyk U. Intestinal epithelium, intraepithelial lymphocytes and the gut microbiota-Key players in the pathogenesis of celiac disease. *World J Gastroenterol.* 2017; 23(42):7505-18.
 46. De Palma G, Capilla A, Nadal I, Nova E, Pozo T, Varea V, et al. Interplay between human leukocyte antigen genes and the microbial colonization process of the newborn intestine. *Curr Issues Mol Biol.* 2010; 12(1):1-10.
 47. Ivarsson A, Hernell O, Stenlund H, Persson LÅ. Breast-feeding protects against celiac disease. *A J Clin Nutr.*

- 2002; 75(5):914-21.
48. De Palma G, Capilla A, Nova E, Castillejo G, Varea V, Pozo T, et al. Influence of milk-feeding type and genetic risk of developing coeliac disease on intestinal microbiota of infants: the PROFICEL study. *Plos One*. 2012; 7(2):e30791.
 49. Demuth H-U, McIntosh CH, Pederson RA. Type 2 diabetes—therapy with dipeptidyl peptidase IV inhibitors. *Biochim Biophys Acta*. 2005; 1751(1):33-44.
 50. Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. *Crit Rev Clin Lab Sci*. 2003; 40(3):209-94.
 51. Olivares M, Schüppel V, Hassan AM, Beaumont M, Neyrinck AM, Bindels LB, et al. The potential role of the dipeptidyl peptidase-4-like activity from the gut microbiota on the host health. *Front Microbiol*. 2018; 9:1900.
 52. Fteita D, Könönen E, Gürsoy M, Söderling E, Gürsoy UK. Does estradiol have an impact on the dipeptidyl peptidase IV enzyme activity of the *Prevotella intermedia* group bacteria? *Anaerobe*. 2015; 36:14-8.
 53. Üstün Aytekin Ö, Arısoy S, Aytekin AÖ, Yıldız E. Statistical optimization of cell disruption techniques for releasing intracellular X-prolyl dipeptidyl aminopeptidase from *Lactococcus lactis* spp. *lactis*. *Ultrason Sonochem*. 2016; 29:163-71.
 54. Hildebrandt M, Rose M, Rüter J, Salama A, Mönnikes H, Klapp B. Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. *Scand J Gastroenterol*. 2001; 36(10):1067-72.
 55. Sorbara MT, Pamer EG. Interbacterial mechanisms of colonization resistance and the strategies pathogens use to overcome them. *Mucosal Immunol*. 2019; 12(3):840.
 56. Lindfors K, Ciacci C, Kurppa K, Lundin KE, Makharia GK, Mearin ML, et al. Coeliac disease. *Nat Rev Dis Primers*. 2019; 5:3.
 57. Rinninella E, Raoul P, Cintoni M, Franceschi F, Abele G, Miggiano D, et al. What is the healthy gut microbiota composition? a changing ecosystem across age, environment, diet, and diseases. *Microorganisms*. 2019; 7:14.
 58. Fehlner-Peach H, Magnabosco C, Raghavan V, Scher JU, Tett A, Cox LM, et al. Distinct polysaccharide growth profiles of human intestinal *Prevotella copri* isolates. *Cell Host Microbe*. 2019; 26(5):680-90.e5.
 59. Kovatcheva Datchary P, Nilsson A, Akrami R, Lee YS, De Vadder F, Arora T, et al. Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of *Prevotella*. *Cell Metab*. 2015; 22(6):971-82.